Oncology Approvals At US FDA Could Pick Up Over Summer
Executive Summary
Only two novel oncologics have cleared the FDA’s approval bar in 2019, but the Pink Sheet’s user fee tracker shows at least eight candidates under review, along with seven significant new indications and formulations.
You may also be interested in...
Long Hot Summer For Novel Drug Reviews Forecast At US FDA
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Cautious Restart To Venetoclax’s CANOVA Trial In Multiple Myeloma
The US FDA has lifted a partial clinical hold on one study of venetoclax in multiple myeloma, but other trials of the first-in-class agent in the potential additional indication remain on hold.
US FDA's Real-Time Oncology Review Times Coming Into Focus
With approval of AbbVie Inc./Genentech Inc.'s Venclexta as seventh under RTOR pilot, a roughly two-month median review time under the program could be taking shape.